OncoTherapy Science, Inc.

TSE:4564 Stock Report

Market Cap: JP¥6.8b

OncoTherapy Science Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Junichi Shimada

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.5yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure8.5yrs

Recent management updates

Recent updates

Is OncoTherapy Science (TSE:4564) In A Good Position To Invest In Growth?

Oct 11
Is OncoTherapy Science (TSE:4564) In A Good Position To Invest In Growth?

We're A Little Worried About OncoTherapy Science's (TSE:4564) Cash Burn Rate

Mar 01
We're A Little Worried About OncoTherapy Science's (TSE:4564) Cash Burn Rate

CEO

Junichi Shimada (63 yo)

2.5yrs

Tenure

Mr. Junichi Shimada is President, Chief Executive Officer of OncoTherapy Science, Inc. since July 2022 and serves as its Director from June 2022.

Board Members

NamePositionTenureCompensationOwnership
Hatsuo Kato
Executive Chairman47.8yrsno datano data
Junichi Shimada
President2.6yrsno datano data
Jae-Hyun Park
Chief Scientific Officer & Director6.6yrsno datano data
Yuichi Komine
Independent External Director10.3yrsno datano data
Miyako Takagi
External Auditor20.6yrsno data0.011%
¥ 774.9k
Teruhisa Tajima
External Auditor10.3yrsno datano data
Yuka Yamane
Auditor3.6yrsno data0.018%
¥ 1.3m
Yoshio Miki
Independent External Director2.6yrsno datano data

8.5yrs

Average Tenure

58yo

Average Age

Experienced Board: 4564's board of directors are considered experienced (8.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 06:39
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OncoTherapy Science, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kiyokazu YamazakiIchiyoshi Research Institute Inc.
Toshiyuki IwataMizuho Securities Co., Ltd.